… ® , which uses a cell’s own editing machinery called ADAR (adenosine deaminase acting on RNA) to make specific … the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including …
… ® , which uses a cell’s own editing machinery called ADAR (adenosine deaminase acting on RNA) to make specific … the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including …
… Axiomer®, which uses a cell’s own editing machinery called ADAR (adenosine deaminase acting on RNA) to make specific … the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including …
Divestment of sepofarsen and ultevursen completed – Théa to continue development of sepofarsen and ultevursen for patients with LCA10 and Usher syndrome
… Annual General Meeting of Shareholders and Provides Leadership Updates Annual General Meeting of Shareholders to … ® , which uses a cell’s own editing machinery called ADAR (adenosine deaminase acting on RNA) to make specific …
Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas; initial pipeline targets to be disclosed in early 2023 with Analyst and Investor R&D event to be held in Q1 2023
Management Team appointments and p